Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054298 · ClinicalTrials.gov registry record · Phase 1
CAR T Cells in Mesothelin Expressing Cancers
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT03054298: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03054298 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03054298, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
Interventions
- BIOLOGICAL huCART-meso cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03054298
The ClinicalTrials.gov registry entry for NCT03054298 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which huCART-meso cells is the first listed.
NCT03054298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03054298 about?
NCT03054298 is a clinical study titled "CAR T Cells in Mesothelin Expressing Cancers". Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
What is the current status of trial NCT03054298?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2017-04-06. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT03054298?
The interventions under investigation include: huCART-meso cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03054298?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.